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Abstract
Background:  The chemokine and bone marrow-homing receptor CXCR4 is implicated in
metastases of various cancers. This study was conducted to analyze the association of CXCR4
expression with hepatocellular carcinoma (HCC) bone metastasis and patient survival.
Methods: Tumor tissue from HCC patients with (n = 43) and without (n = 138) bone metastasis
was subjected to immunohistochemical staining for CXCR4 using tissue microarrays.
Immunoreactivity was evaluated semi-quantitatively. A receiver-operating characteristic-based
approach and logistical regression analysis were used to determine the predictive value of
clinicopathologic factors, including CXCR4 expression, in bone metastasis. Patient survival was
analyzed by Kaplan-Meier curves and log-rank tests.
Results: CXCR4 overexpression was detected in 34 of 43 (79.1%) patients with bone metastases
and in 57 of 138 (41.3%) without bone metastases. CXCR4 expression correlated with (correlation
coefficient: 0.551, P < 0.001) and was predictive of HCC bone metastases (AUC: 0.689; 95%CI:
0.601 – 0.776; P < 0.001). CXCR4 staining intensity correlated with the bone metastasis-free
survival (correlation coefficient: -0.359; P = 0.018). CXCR4 overexpression in primary tumors (n
= 91) decreased overall median survival (18.0 months vs. 36.0 months, P <0.001). Multivariable
analysis identified CXCR4 as a strong, independent risk factor for reduced disease-free survival
(relative risk [RR]: 5.440; P = 0.023) and overall survival (RR: 7.082; P = 0.001).
Conclusion: CXCR4 expression in primary HCCs may be an independent risk factor for bone
metastasis and may be associated with poor clinical outcome.
Background
Chemokines are chemotactic factors that regulate the
development and migration of various cell types. These
factors are classified into four groups (CXC, CX3C, CC,
and C) based on the position of the first two highly con-
served cysteines (C) in the amino acid sequence (where X
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is any amino acid residue). The chemical effects of chem-
okines on target cells are mediated by G protein-coupled
receptors (GPCRs) that contain seven transmembrane
domains and participate in attracting leukocytes to differ-
ent organs [1]. The chemokine receptor CXCR4 is a 352-
amino acid rhodopsin-like GPCR belonging to a large
superfamily of GPCRs. CXCR4 selectively binds the CXC
chemokine, stromal cell-derived factor 1 (SDF-1). SDF-1
secretion by stromal cells attracts cancer cells via stimula-
tion of the CXCR4 receptor, which is upregulated in
tumor cells. Binding of SDF-1 to CXCR4 induces migra-
tion of cancer cells into normal tissue, where the cells pro-
liferate and form metastatic tumors [2]. Schimanski and
colleagues [3] found that dissemination of hepatocellular
carcinoma (HCC) may be mediated via the chemokine
receptor CXCR4, but the relationship between CXCR4
expression and bone metastases of HCC remains
unknown. Recent studies reveal that CXCR4 overexpres-
sion may be associated with bone or bone marrow metas-
tasis and correlated with poor survival in various solid
malignancies [4-11]. Blocking the CXCR4/SDF-1 pathway
may prevent the formation of bone metastases [12].
In the past, bone metastases were considered uncommon
in patients with HCC. However, due to improved dura-
tion of control of intrahepatic primary tumors and due to
improved imaging, bone metastases from HCC are now
more frequently noted [13,14]. Early diagnosis of bone
metastasis is important for the therapeutic regimen and
for assessing prognosis. HCC patients with bone metas-
tases not only have a poor prognosis, but also suffer from
pain and other significant symptoms that are detrimental
to quality of life. Prevention of such bone metastases will
depend on a full understanding of the molecular mecha-
nisms that underlie HCC metastases to bone.
We hypothesize that CXCR4 participates in HCC cell
homing to bone or bone marrow and that primary tumor
CXCR4 expression correlates with clinical metastasis to
bone. In this study, we examined the role of high CXCR4
expression levels in HCC bone metastasis and survival.
Methods
Patients
From May 1999 to October 2007, 43 patients with patho-
logically proven HCC underwent hepatectomy at the Liver
Cancer Institute, Fudan University. All patients had bone
metastases and complained of pain in the days following
the hepatectomy. All patients received external-beam radi-
ation therapy for their bone lesions at the Department of
Radiation Oncology, Zhongshan Hospital, Fudan Univer-
sity. During the same time, 138 patients with pathologi-
cally proven HCC who underwent hepatectomy but did
not have bone metastasis were retrieved from a prospec-
tively designed database. Of the 138 patients, 25 patients
had distal metastases but without bone involvement and
113 patients were without metastasis. This study was
approved by the ethical review board of Zhongshan Hos-
pital, Fudan University. The patient population consisted
of 156 men and 25 women with a mean age of 50.7 ± 10.4
years (range: 12 – 86 years). Among these patients, 37
men and 6 women had bone metastases, and these
patients had a mean age of 50.4 ± 9.5 years (range: 32 –
69 years). Tumor size was based on the largest dimension
of the tumor. Satellite lesions were defined by the pres-
ence of two or more nodules, including intrahepatic
metastases. Vascular invasion was determined by micro-
scopic examination of the resected specimen. Portal vein
thrombosis was identified by macroscopic examination of
the resected specimen. Of the 181 HCC patients, 144 were
positive for the hepatitis B surface antigen. All patients
had Child-Pugh A liver function.
Diagnosis of bone metastases was based on the history of
HCC, presence of symptoms, and radiologic imaging
studies. Bone metastases were not confirmed by histolog-
ical testing. Patients with primary lesions or seeding neo-
plasm invading bone were excluded from this study. All
patients were screened by technetium-99m bone scintig-
raphy for possible bone metastasis. Bone scintigraphy is
not specific for metastatic disease, and positive findings
must be confirmed using other imaging studies. A con-
firmatory study (MRI, as a first choice, or CT) is obligatory
in this study and is especially important to determine the
presence or absence of soft-tissue extension with bone
destruction or spinal cord compression as well as the
extent of osteolytic or osteoblastic metastases.
Tissue Microarray
The tissue microarray (TMA) technique was performed as
described elsewhere [15]. Hematoxylin and eosin-stained
slides were screened to identify optimal tumor tissue for
analysis. TMA slides were then constructed (in collabora-
tion with Shanghai Biochip Company, Ltd, Shanghai,
China). Two cores of tissue were collected from non-
necrotic areas of tumor foci (as shown in Figure 1A) in
each formalin-fixed, paraffin-embedded HCC sample.
Cores were collected with punch cores with a longest
dimension of 1.0 mm. Sections (4 μm) of the resulting
TMA blocks were made using standard techniques. Suffi-
cient tumor tissue was available and analyzed in all 181
cases.
Immunohistochemistry
Immunohistochemistry was performed with a two-step
method using primary antibody and heat-induced anti-
gen-retrieval procedures. Mouse monoclonal antibody to
human CXCR4 served as the primary antibody (Cat. No.
MAB172, Clone 44716, R & D Systems, Minneapolis, MN,
USA). Tissue was incubated with anti-CXCR4 antibodyBMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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CXCR4 expression in HCC TMAs Figure 1
CXCR4 expression in HCC TMAs. Representative CXCR4 staining. (A): CXCR4 staining in a single tissue core with a 1-
mm diameter (× 50). (B): Cytoplasmic CXCR4 staining. (C): Nuclear CXCR4 staining. (D-G): Examples of weak (+) (D), mod-
erate (++) (E), strong (+++) (F), and very strong staining (++++) (G). All images are × 200 magnification unless otherwise 
noted.BMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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(1:1,000) overnight at 4°C. The primary antibody was
then removed, and the components of the Envision-plus
detection system were applied, along with a polymer-
linked anti-mouse antibody (EnVision+/HRP/Mo, Dako,
Glostrup, Denmark). Reaction products were visualized
by incubation with 3, 3'-diaminobenzidine. Sections were
then counterstained with hematoxylin, dehydrated, and
mounted.
Scoring of CXCR4 Expression
Slides were examined by three independent, blinded
observers using a Leica DMIRE2 microscope (Leica
DMIRE2, CCD: DFC 420FX, Germany). The intensity of
staining and percentage of positive tumor cells were deter-
mined by each observer, and the average of three scores
was calculated. The intensity of staining (brown color)
was scored semi-quantitatively as follows: +, weak; ++,
medium; +++, strong; and ++++, very strong. Samples
receiving a score of ++ or greater were considered CXCR4-
positive [16]. An overall immunostaining score was calcu-
lated by multiplying the percentage of positive tumor cells
(0 – 100) by the staining intensity (Grade 1 – 4), produc-
ing a score in the range of 0 – 400 [17].
Follow-Up Assessments
Follow-up assessments were performed at 3-month inter-
vals after hepatectomy. At every visit a history was col-
lected, and a physical examination was performed. Chest
radiography and ultrasonographic examination of the
liver were performed at 6 months. Bone scintigraphy was
performed when the patient complained of pain. Labora-
tory tests (liver function, α-fetoprotein, and routine blood
tests) were carried out every 3 months. The median fol-
low-up times of HCC patients with and without bone
metastasis were 20.0 months and 23.5 months, respec-
tively.
Statistical Analysis
Patients' overall survival (OS) was defined by the interval
from the date of hepatectomy to the date of death regard-
less of cause or the time elapsed since the last follow-up
appointment. Disease-free survival (DFS) was calculated
from the date of operation to the date of recurrence,
metastasis, or death. Bone metastasis-free survival was cal-
culated from the date of surgery to the date of bone metas-
tasis or death. All calculations were performed with SPSS
15.0 for Windows. Pearson χ2 test or Fisher exact test was
used to compare qualitative variables. Quantitative varia-
bles were analyzed using the Student's t test. Logistical
regression analysis and receiver operating characteristic
(ROC) curves were used to determine the predictive value
of parameters. Kaplan-Meier analysis was used to deter-
mine OS, DFS, and bone metastasis-free survival. Survival
outcomes between patient subgroups were compared
using the log-rank test. Multivariate analysis with the Cox
regression model was performed to identify the clinico-
pathologic factors that independently predicted survival.




Statistical analysis of HCC patients with bone metastases
and without metastases revealed that these two groups sig-
nificantly differed in the presence of satellite lesions, mar-
gin status, vascular invasion, UICC T stage, Edmondson
grade, and CXCR4 status. CXCR4 expression was higher in
patients with bone metastases than in those with distal
metastases, but without bone involvement (Table 1).
CXCR4 Expression
Of the 181 tumor samples examined, 91 (50.3%) were
positive for CXCR4 and 90 (49.7%) were negative. CXCR4
staining was detected in the cytoplasm (Figure 1B) and
nucleus (Figure 1C), although it was primarily present in
the former. Normal tissue adjacent to tumor cells occa-
sionally showed weak CXCR4 staining in the cytoplasm.
CXCR4 overexpression was detected in 34 of 43 (79.1%)
patients with bone metastases and in 57 of 138 (41.3%)
without bone metastases. Of the 138 patients without
bone metastases, positive expression of CXCR4 was
detected in 43 of 113 (38.1%) HCC patients without
metastases and in 14 of 25 (56.0%) HCC patients with
distal metastases but without bone involvement. In addi-
tion, CXCR4 expression much higher in patients with
bone metastases than in those without metastases (P <
0.001) or those with distal metastases but without bone
involvement (P = 0.044). The overall CXCR4 immunos-
taining score (i.e., the product of the percent positive cells
and staining intensity) was 210 ± 93.4 (median: 225;
range: 49 – 400) in patients with bone metastases and 163
± 91.0 (median: 176; range: 43 – 304) in those with distal
metastases but without bone involvement (P = 0.048).
Analysis of the association between CXCR4 expression
and clinicopathological factors among the 181 HCC
patients revealed that bone and hilar lymph node metas-
tases were strongly associated with CXCR4 expression
(Table 2). The extent of CXCR4 overexpression correlated
with bone metastases (correlation coefficient: 0.551; P <
0.001), margin status (correlation coefficient: 0.206;P =
0.005), and hilar lymph node metastases (correlation
coefficient: 0.198; P = 0.008).
Predictors of Bone Metastasis
Bone metastases from HCC correlated with UICC T stage
(correlation coefficient: 0.290, P < 0.001), satellite lesions
(correlation coefficient: 0.289, P < 0.001), vascular inva-
sion (correlation coefficient: 0.171, P = 0.022), and mar-
gins (correlation coefficient: 0.151, P = 0.042). In
addition, bone metastases strongly correlated withBMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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Table 1: Clinicopathologic factors related to bone metastases in 181 HCC patients
HCC Bone Metastases
Clinicopathologic Parameters No. of Cases Negative (n = 138) P Value
(P1, P2)§
A* (n = 113) B* (n = 25) Positive
(n = 43)
Age (y)
≤ 60 153 94 (83.2%) 21 (84.0%) 38 (88.4%) P1 = 0.422
> 60 28 19 (16.8%) 4 (16.0%) 5 (11.6%) P2 = 0.434
Gender
Female 25 15 (13.3%) 4 (16.0%) 6 (14.0%) P1= 0.912
Male 156 98 (86.7%) 21 (84.0%) 37 (86.0%) P2 = 0.540
HBsAg 
Negative 37 22 (19.5%) 5 (20.0%) 10 (23.3%) P1= 0.601
Positive 144 91 (80.5%) 20 (80.0%) 33 (76.7%) P2 = 0.755
AFP (ng/mL) 181
≤ 20 48 28 (24.8%) 7 (28.0%) 13 (30.2%) P1= 0.544
20 – 400 59 39 (34.5%) 9 (36.0%) 11 (25.6%) P2 = 0.648
≥ 400 74 46 (40.7%) 9 (36.0%) 19 (44.2%)
Cirrhosis
Absence 45 30 (26.5%) 6 (24.0%) 9 (20.9%) P1= 0.469
Presence 136 83 (73.5%) 19 (76.0%) 34 (79.1%) P2 = 0.768
Satellite Lesion
Absence 127 94 (83.2%) 13 (52.0%) 20 (46.5%) P1< 0.001
Presence 54 19 (16.8%) 12 (48.0%) 23 (53.5%) P2 = 0.662
Tumor Size (cm) 181 6.04 ± 3.57 6.92 ± 3.34 7.26 ± 3.19 P1= 0.051
P2 = 0.676
Margins
Clear 79 56 (49.6%) 10 (40.0%) 13 (30.2%) P1= 0.030
Involved 102 57 (50.4%) 15 (60.0%) 30 (69.8%) P2 = 0.412
Vascular invasion
Absence 95 70 (61.9%) 9 (36.0%) 16 (37.2%) P1= 0.006
Presence 86 43 (38.1%) 16 (64.0%) 27 (62.8%) P2 = 0.921
Portal Vein Thrombosis
Absence 153 97 (85.8%) 20 (80.0%) 36 (83.7%) P1= 0.739
Presence 28 16 (14.2%) 5 (20.0%) 7 (16.3%) P2 = 0.698
Hilar lymph nodes
Absence 170 109 (96.5%) 23 (92.0%) 38 (88.4%) P1= 0.066
Presence 11 4 (3.5%) 2 (8.0%) 5 (11.6%) P2 = 0.488
UICC T stage 
T1 91 74 (65.5%) 7 (28.0%) 10 (23.3%) P1< 0.001
T2 38 17 (15.0%) 8 (32.0%) 13 (30.2%) P2 = 0.856
T3 52 22 (19.5%) 10 (40.0%) 20 (46.5%)
Edmondson grade
Low (I/II) 118 81 (71.7%) 15 (60.0%) 22 (51.2%) P1= 0.016
High (III/IV) 63 32 (28.3%) 10 (40.0%) 21 (48.8%) P2 = 0.481
CXCR4
Negative 90 70 (61.9%) 11 (44.0%) 9 (20.9%) P1< 0.001
Positive 91 43 (38.1%) 14 (56.0%) 34 (79.1%) P2 = 0.044
* A: HCC without metastasis; B: Distal metastatic HCC without bone involvement.
§ P1: Statistical analysis of HCC patients with bone metastases (n = 43) and without metastases (n = 113).
P2: Statistical analysis of distal metastatic HCC without bone involvement (n = 25) and HCC patients with bone metastases (n = 43).
# Student t test.
 Significant P value.BMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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CXCR4 expression and staining intensity (correlation
coefficient: 0.551, P < 0.001). ROC curve analysis was per-
formed for these clinicopathological factors. The area
under the curve (AUC) and the 95% confidence interval
(CI) were used to assess the power of these clinicopatho-
logical factors for predicting bone metastases (Figure 2
and Table 3). ROC analysis confirmed that CXCR4 status
had good accuracy in predicting bone metastases (AUC:
0.689; 95%CI: 0.601 – 0.776; P < 0.001). However,
CXCR4 expression did not correlate with the number of
bone metastases (P = 0.832) or the site of bone metastases
(P = 0.104).
CXCR4 Expression and Survival
Log-rank tests of Kaplan-Meier curves revealed that, after
hepatectomy, among all 181 HCC patients, those with
positive CXCR4 expression had a poorer OS and DFS
(Log-rank P < 0.001, Figure 3A and 3B). Similar results
were obtained for the 43 HCC patients with bone metas-
tases (Figure 3C and 3D). CXCR4 expression level corre-
Table 2: Clinicopathologic factors related to CXCR4 expression in 181 HCC patients
CXCR4 Expression
Clinicopathologic Parameters No. of Cases Negative (n = 90) Positive (n = 91) P
Age (y)
≤ 60 153 76 (49.7%) 77 (50.3%) 0.975
> 60 28 14 (50.0%) 14 (50.0%)
Gender
Female 25 16 (64.0%) 9 (36.0%) 0.124
Male 156 74 (47.4%) 82 (52.6%)
HBsAg
Negative 37 22 (59.5%) 15 (40.5%) 0.184
Positive 144 68 (47.2%) 76 (52.8%)
AFP(ng/mL, mean ± SD) 181 4941.25 ± 13475.41 3375.54 ± 11340.86 0.396
≤ 20 48 18 (37.5%) 30 (62.5%) 0.017*
20 – 400 59 26 (44.1%) 33 (55.9%)
≥ 400 74 46 (62.2%) 28 (37.8%)
Cirrhosis
Absence 45 22 (48.9%) 23 (51.1%) 0.897
Presence 136 68 (50.0%) 68 (50.0%)
Satellite lesion
Absence 127 65 (51.2%) 62 (48.8%) 0.548
Presence 54 25 (46.3%) 29 (53.7%)
Tumor size (cm) 181 6.15 ± 3.66 6.75 ± 3.28 0.247
Margins
Clear 79 45 (57.0%) 34 (43.0%) 0.087
Involved 102 45 (44.1%) 57 (55.9%)
Vascular invasion
Absence 95 44 (46.3%) 51 (53.7%) 0.335
Presence 86 46 (53.5%) 40 (46.5%)
Portal Vein Thrombosis
Absence 153 72 (47.1%) 81 (52.9%) 0.094
Presence 28 18 (64.3%) 10 (35.7%)
Hilar Lymph Nodes
Absence 170 89 (52.4%) 81 (47.6%) 0.005*
Presence 11 1 (9.1%) 10 (90.9%)
UICC T stage
T1 91 45 (49.5%) 46 (50.5%) 0.693
T2 38 17 (44.7%) 21 (55.3%)
T3 52 28 (53.8%) 24 (46.2%)
Edmondson grade
Low (I/II) 118 61 (51.7%) 57 (48.3%) 0.468
High (III/IV) 63 29 (46.0%) 34 (54.0%)
Bone Metastases
Absence 138 81 (58.7%) 57 (41.3%) < 0.001*
Presence 43 9 (20.9%) 34 (79.1%)
* Significant P value.BMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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lated with bone metastasis-free survival (correlation
coefficient: -0.359, P = 0.018). Multivariate analysis iden-
tified CXCR4 expression (RR: 7.082; P = 0.001) and UICC
T stage (P = 0.001) as the two factors that independently
predicted survival of HCC patients with bone metastasis.
CXCR4 (RR: 5.440; P = 0.023) and UICC T3 stage (P =
0.010) were the independent risk factors that most
strongly associated with reduced disease-free survival in
patients with bone metastasis.
Discussion
HCC is the most common primary tumor of the liver.
Once HCC cells spread to and become established in
bone, HCC bone metastases begin to interfere with the
normal health and strength of the bones. This often leads
to bone pain, fracture, or other complications that can sig-
nificantly impair a patient's health and that increase mor-
bidity and mortality in HCC patients. The frequency of
bone metastasis in HCC patients with extrahepatic metas-
tases was estimated to be 38.5% [14]. Early prediction or
detection of bone metastases can help to determine the
best treatment strategy and avoid complications caused by
the metastases.
The mechanisms of cancer metastasis are complex, lead-
ing to continual expansion of the "seed and soil" hypoth-
esis upon new discoveries about this process. After
metastatic cells have passed through vascular channels
and implanted in the bone, a favorable "soil" may be
responsible for further growth and proliferation. The
establishment of bone metastasis results from close inter-
action between metastatic tumor cells and the unique
environment of the bone and bone marrow [18]. The for-
mation of aggressive bone metastases is tightly associated
with a distinctive gene expression profile [19]. The chem-
okine receptor CXCR4 has been implicated in the mecha-
ROC analysis Figure 2
ROC analysis. ROC analysis of CXCR4, UICC T stage, satellite lesion, and vascular invasion. The AUC of all parameters was 
> 0.5, indicating that they were predictive of HCC bone metastases.BMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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Table 3: Area under the curve (95% Confidence Interval) demonstrating the discriminatory power of each clinicopathologic factor for 
predicting HCC bone metastases
Clinicopathologic Factor AUC SE 95%CI P
CXCR4 Status 0.689 0.045 0.601 – 0.776 <0.001*
UICCT Stage 0.684 0.046 0.595 – 0.773 <0.001*
Satellite Lesion 0.655 0.050 0.557 – 0.753 0.002*
Vascular Invasion 0.600 0.049 0.504 – 0.697 0.048*
Edmondson Grade 0.593 0.049 0.498 – 0.688 0.066
Margins 0.588 0.049 0.492 – 0.683 0.082
* Significant P value
Kaplan-Meier analysis of overall and disease-free survival Figure 3
Kaplan-Meier analysis of overall and disease-free survival. (A and B): Association of CXCR4 expression with overall 
(A) and disease-free (B) survival of 181 HCC patients. (C and D): Association of CXCR4 expression with overall (C) and dis-
ease-free (D) survival of the 43 HCC patients with bone metastases.BMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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nism underlying tumor cell metastasis to bone. The
interaction between the organ microenvironment and
cancer cells appears to be fundamental for establishing
metastatic growth. Tumors with higher CXCR4 expression
are more prone to clinical metastasis than those with
lower expression [20,21].
Cancer stem cells express CXCR4 at their surface. As a
result, the SDF-1/CXCR4 axis participates in directing the
metastasis of these cells to bones that express high levels
of SDF-1 [22]. High levels of SDF-1 are present in organs
that are commonly invaded by metastasizing cells, such as
the bones, and these high SDF-1 levels attract CXCR4-pos-
itive tumor cells. The interaction between SDF-1 and
CXCR4 leads to the activation of specific signaling path-
ways, allowing for homing and metastatic progression.
CXCR4 overexpression enhances bone tumor growth and
osteolysis [23]. It also significantly decreases bone metas-
tasis-free survival in vivo [24]. CXCR4 may enhance inva-
sive signals and metastatic growth in the bone
microenvironment.
Here, we found that high CXCR4 expression in HCC spec-
imens is clinically correlated with bone metastases.
CXCR4 may play an important role in the metastasis of
HCC by promoting the migration of tumor cells [25].
CXCR4-overexpressing cells were more likely to metasta-
size, notably into bone marrow [26]. Prostate cancers, and
perhaps other neoplasms, may rely upon the SDF-1/
CXCR4 pathway to spread to bone [5]. Our findings sug-
gest that HCC also uses the same pathway to spread to
bone.
Using a ROC-based approach and logistical regression
analysis to select the most relevant factors from a panel of
clinicopathologic factors, we found that CXCR4, UICC T
stage, satellite lesions, and vascular invasion were predic-
tors of bone metastases from HCC. CXCR4 expression, in
particular, was a superior predictor of bone metastasis and
increased in primary HCC tumors with clinical evidence
of bone metastases. These results are consistent with our
hypothesis that CXCR4 is important for HCC cell homing
to bone or bone marrow, and they suggest that CXCR4
overexpression in HCC is associated with a higher rate of
bone metastases. Here, we report for the first time that
overexpression of CXCR4 is significantly correlated with
HCC bone metastases and that positive expression of
CXCR4 may reduce HCC patient survival. We also found
that the level of CXCR4 expression correlated with bone
metastasis-free survival; i.e., HCC patients with tumor tis-
sue exhibiting strong CXCR4 expression may experience
bone metastases sooner than those with lower levels of
expression. Smith and colleagues found that CXCR4
inhibitors improve treatment of patients with primary
and metastatic cancer [27]. Thus, blocking the CXCR4/
SDF-1 pathway would be expected to prevent bone metas-
tases. The patients whom we collected for this study are
not consecutive patients, which may affect our conclu-
sions.
During the early establishment of metastases, bone is
destroyed by osteoclasts. Bisphosphonates can inhibit the
activity of osteoclasts, and bisphosphonate treatment is a
well-established supportive therapy for reducing the fre-
quency and severity of skeletal complications in patients
with bone metastases from different cancers [28].
Bisphosphonates, such as clodronate, are potent inhibi-
tors of bone resorption. Clodronate has been used for
many years to reduce skeletal complications of bony
metastases and also has potential for inhibiting bone
metastasis. Breast cancer patients who receive a 2-year
treatment of clodronate have a significantly decreased
occurrence of bone metastases compared to patients
receiving placebo [29]. Diel and coworkers [30] also
found the incidence of osseous metastases was signifi-
cantly lower in the clodronate-treated breast cancer
patients than in control patients. Our findings suggest that
HCC patients at high risk of bone metastases can be iden-
tified by analyzing CXCR4 expression and other clinico-
pathological factors. Once identified, these high-risk HCC
patients could receive oral clodronate, which may reduce
the risk of bone metastases.
In this study, we found that some HCC patients exhibited
high levels of of CXCR4 expression but did not have bone
metastases. This may be attributable to low levels of SDF-
1 in the bones or bone marrow, a condition that would
block the CXCR4/SDF-1 pathway. However, we did not
measure SDF-1 levels in the bone of HCC patients. Deter-
mining whether SDF-1 levels predict bone metastasis in
HCC patients will require further study. In addition,
whether plasma levels of SDF-1 correlate with SDF-1 lev-
els in the bone or bone marrow should be determined. In
this way, analysis of CXCR4 expression and plasma SDF-
1 may be combined to more accurately predict bone
metastasis of HCC.
In summary, the clinical findings from this study strongly
support a homing or signaling mechanism for HCC bone
metastasis. In HCC, the CXCR4 chemokine receptor may
facilitate metastasis to the bone, where the CXCR4 ligand
is abundantly produced. CXCR4 is novel prognostic
marker for bone metastases after curative resection of
HCC. CXCR4 may not only prove useful for predicting
bone metastasis, but may also serve as a therapeutic target
for HCC.
Conclusion
Our study results showed that CXCR4 expression signifi-
cantly correlated with bone metastasis in HCC. CXCR4BMC Cancer 2009, 9:176 http://www.biomedcentral.com/1471-2407/9/176
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overexpression in primary HCCs may be an independent
risk factor for bone metastasis and may be associated with
poor clinical outcome. CXCR4 may serve as a therapeutic
target for HCC.
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